During the 1980s and '90s, Schering-Plough refined its focus on four key therapeutic areas and integrating new technologies to achieve important pharmaceutical advances in antihistamines, corticosteroids, antibiotics, anti-infectives and antiviral products.

CNN: Schering-Plough facts

Akorn is a niche generic pharmaceutical company that develops, manufactures and markets pharmaceutical products in the areas of ophthalmology, antidotes and anti-infectives in addition to controlled substances for pain management and anesthesia.

FORBES: Akorn Stock Has Healthy Upside

And it's also an indication that large pharma companies are willing to pay significant premiums even for acute anti-infectives, which was an area up until six months ago they really had gotten out of.

FORBES: The Next Antibiotic Buyout?